6-氯哒嗪-3-甲酰胺 | 66346-83-6

• 物质功能分类: 医药中间体 - 哒嗪类化合物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 6-氯哒嗪-3-甲酰胺
• 中文别名: 6-氯吡嗪-3-羧酰胺
• 英文名称: 6-chloro-3-pyridazinecarboxamide
• 英文别名: 6-chloropyridazine-3-carboxamide；3-Chloro-pyridazine-6-carboxamide
• CAS: 66346-83-6
• 化学式: C₅H₄ClN₃O
• mdl: MFCD09258882
• 分子量: 157.559
• InChiKey: NMCKZYHQHAZHIO-UHFFFAOYSA-N

物化性质

• 熔点：
  232-234 °C(Solv: water (7732-18-5))
• 沸点：
  424.6±30.0 °C(Predicted)
• 密度：
  1.478±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  68.9
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Chloropyridazine-3-carboxamide
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Chloropyridazine-3-carboxamide
CAS number: 66346-83-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H4ClN3O
Molecular weight: 157.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

制备以6-氯哒嗪-3-甲酸甲酯为起始物料与氨水一步反应可制得6-氯哒嗪-3-甲酰胺；或先以6-氯哒嗪-3-甲酸经草酰氯反应生成6-氯哒嗪-3-甲酰氯，再与氨水反应目标化合物6-氯哒嗪-3-甲酰胺。6-氯哒嗪-3-甲酰胺的合成反应式如下图所示：

实验操作如下：

1. 称取适量6-氯哒嗪-3-甲酸甲酯加入高压反应釜中。
2. 依次加入乙醇和25%氨水，并通氮气置换釜内空气三次。
3. 搅拌升温至100℃，反应六小时后降温至5℃，搅拌一小时以促结晶析出。
4. 抽滤，用水洗涤产物，最后在50℃下进行真空干燥处理，即可得到6-氯哒嗪-3-甲酰胺。

反应信息

• 作为反应物：
  描述：

  6-氯哒嗪-3-甲酰胺 在 吡啶 、 三氟乙酸酐 作用下， 以 二氯甲烷 为溶剂， 以59%的产率得到3-氰基-6-氯哒嗪
  参考文献：
  名称：

  Aromatic compounds and pharmaceutical compositions containing them

  摘要：

  该发明涉及公式I的化合物及其药学上可接受的盐和体内可水解的酯和酰胺，以及它们的制备方法、作为治疗剂的用途和含有它们的药物组合物。在公式I中，A是一个环系统，其中--CH(R^3)N(R^2)B--R^1和--OR^4基团在环碳原子上以1,2的关系定位。B是一个具有R^1在与--CH(R^3)N(R^2)--连接基团的1,3或1,4关系的环系统。R^2是氢或C1-C6-烷基，R^3是氢、甲基或乙基，R^4是C1-C6-烷基、C1-C6-环烷基-C1-C3-烷基、C3-C7-环烷基、--NR^2的N-氧化物（在化学上可能的情况下）或含硫环的S-氧化物（在化学上可能的情况下）。A、B、R^1、R^2、R^3和R^4可以被取代，如规范中定义的那样。

  公开号：

  US05994353A1
• 作为产物：
  描述：

  6-氯哒嗪-3-甲酸甲酯 在 氨 作用下， 以 甲醇 为溶剂， 反应 0.5h， 以97%的产率得到6-氯哒嗪-3-甲酰胺
  参考文献：
  名称：

  Konno, Shoetsu; Sagi, Mataichi; Siga, Futoshi, Heterocycles, 1992, vol. 34, # 2, p. 225 - 228

  摘要：

  DOI：

文献信息

• Substituted Pyrrolidine-2-Carboxamides
  申请人：Ding Qingjie

  公开号：US20100075948A1

  公开（公告）日：2010-03-25

  There are provided compounds of the formula wherein X, Y, R 1 , R 2 , R 3 , R 3 , R 4 , R 5 , R 6 and R 7 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.

  提供了以下式的化合物 其中X、Y、R1、R2、R3、R3、R4、R5、R6和R7如本文所述，以及其对映体和药用可接受的盐和酯。这些化合物可用作抗癌药物。
• Aromatic amine compounds that antagonize the pain enhancing effects of
  申请人：Zeneca Limited

  公开号：US06100258A1

  公开（公告）日：2000-08-08

  Compounds antagonistic of the pain enhancing effects of prostaglandins are disclosed. The compounds comprise an optionally-substituted A ring with a --CH(R.sup.3)N(R.sup.2)B--R.sup.1 and --OD groups positioned in a 1,2 relationship to one another on ring carbon atoms. The 3-position ring-atom is not substituted. B is also an optionally-substituted ring and the group R.sup.1 is positioned on B in a 1,3 or 1,4 relationship with the --CH(R.sup.3)N(R.sup.2)-- linking group. R.sup.1, R.sup.2 and R.sup.3 and D can be a number of different organic or halogen moieties. N-oxides of --NR.sup.2 and S-oxides of sulphur containing rings are disclosed as are processes for the preparation of the compounds, intermediates in their preparation, pharmaceutical compositions containing them, and their use as therapeutic agents.

  抗拮抗前列腺素增强疼痛作用的化合物被披露。这些化合物包括一个可选择取代的A环，其中在环碳原子上，一个--CH(R.sup.3)N(R.sup.2)B--R.sup.1和--OD基团以1,2的关系相互定位。3位环原子未被取代。B也是一个可选择取代的环，基团R.sup.1在B上以1,3或1,4的关系与--CH(R.sup.3)N(R.sup.2)--连接基团定位。R.sup.1、R.sup.2和R.sup.3以及D可以是多种不同的有机或卤素基团。还披露了--NR.sup.2的N-氧化物和含硫环的S-氧化物，以及制备这些化合物、其制备中间体、含有它们的药物组合物以及它们作为治疗剂的用途的方法。
• Heterocyclic compounds as ligands of the GABAA receptor
  申请人：——

  公开号：US20030105081A1

  公开（公告）日：2003-06-05

  Disclosed are heterocyclic compounds of the formula 1 and the pharmaceutically acceptable salts thereof wherein the variables A, V, Y, J, E, X, T, G, Q, W, Z, b, n and m are defined herein. These compounds are highly selective agonists, antagonists or inverse agonists for GABA A brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABA A brain receptor.

  揭示了具有以下公式的杂环化合物及其药用可接受的盐，其中变量A、V、Y、J、E、X、T、G、Q、W、Z、b、n和m在此处被定义。这些化合物是GABA A 脑受体的高度选择性激动剂、拮抗剂或逆激动剂，或者是GABA A 脑受体的激动剂、拮抗剂或逆激动剂的前药。
• Fungicidal pyridazines
  申请人：Eli Lilly and Company

  公开号：US04791110A1

  公开（公告）日：1988-12-13

  Plants are protected from the damaging effects of Phycomycetous fungi by a series of pyridazines of formula ##STR1## wherein R.sup.3 is chloro, bromo, methyl, cyano or iodo; R is chloro, bromo, iodo, methyl, cyano or furan-2-ylmethoxy; R.sup.1 is hydrogen, methyl, ethyl or n-propyl; R.sup.2 is ##STR2## X is fluoro, chloro, bromo or iodo; X.sup.1 and X.sup.2 independently represent X or hydrogen, provided that no more than one of X.sup.1 and X.sup.2 is hydrogen; R.sup.4 is hydrogen, chloro, bromo, methyl or ethyl; R.sup.5 is hydrogen, chloro, methyl, ethyl, chloromethyl or dichloromethyl; or R.sup.4 and R.sup.5 combine with the group to which they are attached to form a C.sub.3 -C.sub.7 cycloalkyl group substituted with a R.sup.1 group; R.sup.6 is hydrogen, chloro, bromo, methyl or ethyl; R.sup.7 is hydrogen, methyl, ethyl, chloromethyl or dichloromethyl; one of m and n is 0 or 1, and the other is 0; p is 0-4.

  植物通过一系列的吡啶嗪化合物的保护作用，防止了Phycomycetous真菌的破坏性影响。其中化学式为##STR1##，其中R.sup.3为氯、溴、甲基、氰基或碘；R为氯、溴、碘、甲基、氰基或呋喃-2-基甲氧基；R.sup.1为氢、甲基、乙基或正丙基；R.sup.2为##STR2##，X为氟、氯、溴或碘；X.sup.1和X.sup.2独立地代表X或氢，前提是X.sup.1和X.sup.2中最多只有一个是氢；R.sup.4为氢、氯、溴、甲基或乙基；R.sup.5为氢、氯、甲基、乙基、氯甲基或二氯甲基；或者R.sup.4和R.sup.5与它们附着的基团结合形成一个取代有R.sup.1基团的C.sub.3 -C.sub.7环烷基；R.sup.6为氢、氯、溴、甲基或乙基；R.sup.7为氢、甲基、乙基、氯甲基或二氯甲基；m和n中的一个为0或1，另一个为0；p为0-4。
• NOVEL COMPOUNDS
  申请人：Buttar David

  公开号：US20080153812A1

  公开（公告）日：2008-06-26

  There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.

  提供了一个式(I)的化合物，或其药用可接受的盐。还提供了制备式1化合物的方法，以及将式1化合物用作药物和用于癌症治疗的用途。